Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges.

Alector Inc (ALEC) stock saw a decline, ending the day at $2.16 which represents a decrease of $-0.04 or -1.82% from the prior close of $2.2. The stock opened at $2.27 and touched a low of $2.06 ...

BofA downgraded Alector (ALEC) to Underperform from Neutral with a price target of $1, down from $9.Don't Miss our Black Friday Offers:Unlock ...

As previously reported, BofA downgraded Alector (ALEC) to Underperform from Neutral with a price target of $1, down from $9, after ALOO2 missed ...

Alector (NASDAQ:ALEC – Free Report) had its price target reduced by HC Wainwright from $35.00 to $7.00 in a report published on Friday, MarketBeat.com reports. They currently have a buy rating on the ...

Despite the trial's failure, Alector secured a $50 million credit facility from Hercules Capital (NYSE:HTGC) Inc., aimed at supporting ongoing research and development efforts. The company ...

Arnon Rosenthal, the Chief Executive Officer of Alector, Inc. (NASDAQ:ALEC), recently reported the sale of 52,172 shares of the company's common stock, totaling approximately $131,442. The sale ...

Vigil Neuroscience's stock dropped after Alector's AL002 failed in Alzheimer's, raising concerns about VG-3927's efficacy.

As of 12:34:05 PM EST. Market Open. Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.

The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a ...

And the first IPO without a fixed share price since the shutdown ended late last month was from Alector, a biotech that is aiming to find new treatments for dementia. Alector fell on its trading ...